OS Therapies (OSTX) Stock Price, News & Analysis

Company Overview

OS Therapies, Inc. is a clinical-stage biotechnology company focused on developing treatments for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults, as well as other solid tumors. The company’s work is aimed at addressing significant unmet medical needs in cancers for which treatment options remain limited.

Its lead investigational product, OST-HER2, is an immunotherapy designed to target tumors that express the HER2 protein. OS Therapies has been evaluating OST-HER2 in clinical studies involving patients with recurrent or metastatic osteosarcoma. The company’s development strategy centers on advancing targeted therapies through clinical testing and potential regulatory approval.

OS Therapies conducts its research and clinical development activities in collaboration with medical institutions and investigators. The company is headquartered in the United States and serves the oncology market through the development of therapies intended for patients with rare and difficult-to-treat cancers.

Key Stats

• Today's Range: $1.64 to $1.68
• 50-Day Range: $1.44 to $1.88
• 52-Week Range: $1.15 to $2.25
• Volume: 170,314 shs
• Average Volume: 645,989 shs
• Market Capitalization: $76.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.33
• Consensus Rating: Moderate Buy

OS Therapies Stock Analysis - MarketRank™

OS Therapies scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OS Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

OS Therapies has a consensus price target of $13.33, representing about 703.2% upside from its current price of $1.66.

Amount of Analyst Coverage

OS Therapies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OS Therapies are expected to grow in the coming year, from ($0.73) to $0.59 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OS Therapies is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OS Therapies is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.07% of the float of OS Therapies has been sold short.

Short Interest Ratio / Days to Cover

OS Therapies has a short interest ratio ("days to cover") of 2.52, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OS Therapies has recently decreased by 23.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OS Therapies does not currently pay a dividend.

Dividend Growth

OS Therapies does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for OS Therapies this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for OSTX on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OS Therapies insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.60% of the stock of OS Therapies is held by insiders.

Percentage Held by Institutions

OS Therapies has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:OSTX
• Previous Symbol: NYSE:OSTX
• CIK: 1795091
• Web: ostherapies.com
• Phone: (410) 297-7793
• Fax: N/A
• Employees: 5
• Year Founded: 2018

Price Target and Rating

• Average Price Target for OS Therapies: $13.33
• High Price Target: $20.00
• Low Price Target: $7.00
• Potential Upside/Downside: +703.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -477.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.18
• Quick Ratio: 0.18

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.17) per share
• Price / Book: -9.76

Miscellaneous

• Outstanding Shares: 46,130,000
• Free Float: 41,698,000
• Market Cap: $76.58 million
• Optionable: N/A
• Beta: -0.68